Rifafour E-275 150mg. 75mg. 400mg. 275mg Tablet
PDF Leaflet Revision Date: 12 April 2018
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary and extrapulmonary tuberculosis.
Dosage (summary)
Adults: 2-5 tablets daily based on weight.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; excreted in breast milk.
Key Drug Interactions
- Saquinavir/ritonavir
- Ketoconazole
- Oral contraceptives
Contraindications
- Hypersensitivity to components
- Jaundice
- Active hepatic disease
- Optic neuritis
- Porphyria
- Children under 13
Common side effects
- Nausea
- Vomiting
- Hepatitis
- Visual disturbances
- Thrombocytopenia
Counselling Points
- Take with water 1 hour before or 2 hours after meals
- Avoid alcohol
- Report any signs of liver damage or visual changes
Serious warnings
- Hepatotoxicity risk
- Severe skin reactions
- Monitor liver function
Important Disclaimer
The Rifafour E-275 150mg. 75mg. 400mg. 275mg Tablet professional information leaflet below is the property of Sanofi-Aventis and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
